CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. By Therapeutic Class
1.3.2. By Formulation
1.3.3. By Type
1.3.4. By Acne Type
1.3.5. By Distribution Channel
1.3.6. By Region
1.3.7. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Top player positioning, 2017
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of acne diseases
3.4.1.2. Unhealthy urban lifestyle
3.4.1.3. Rise in focus on skin care products

3.4.2. Restraints

3.4.2.1. Side effects associated with acne medications
3.4.2.2. Presence of alternatives for acne treatment

3.4.3. Opportunities

3.4.3.1. Opportunities in emerging economies
3.4.3.2. Development of therapeutics with lesser side effects

3.4.4. Impact analyses

3.5. Clinical trials
3.6. Patent analysis (2013-2018)

3.6.1. Patent analysis, by year
3.6.2. Patent analysis for China, by year

CHAPTER 4: ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Retinoid

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type

4.2.2.1. Topical & combination retinoid

4.2.2.1.1. Market size and forecast, by region

4.2.2.2. Oral retinoid (Isotretinoin)

4.2.2.2.1. Market size and forecast, by region

4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country

4.3. Antibiotics

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by type

4.3.2.1. Topical & combination antibiotics

4.3.2.1.1. Market size and forecast, by region

4.3.2.2. Oral antibiotics

4.3.2.2.1. Market size and forecast, by region

4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country

4.4. Salicylic acid

4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Benzoyl Peroxide

4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Other medications

4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

CHAPTER 5: ACNE MEDICATION MARKET, BY FORMULATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Topical medications

5.2.1. Market size and forecast, by region

5.3. Oral medications

5.3.1. Market size and forecast, by region

CHAPTER 6: ACNE MEDICATION MARKET, BY TYPE

6.1. Overview

6.1.1. Market size and forecast

6.2. Prescription medicines

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Over-the-counter medicines

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

CHAPTER 7: ACNE MEDICATION MARKET, BY ACNE TYPE

7.1. Overview

7.1.1. Market size and forecast

7.2. Non-inflammatory acne

7.2.1. Market size and forecast, by region
7.2.2. Market analysis, by country

7.3. Inflammatory acne

7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country

CHAPTER 8: SOURCES: PRIMARY & SECONDARY RESEARCH AND AMR ANALYSIS ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

8.1. Overview

8.1.1. Market size and forecast

8.2. Grocery store

8.2.1. Market size and forecast, by region
8.2.2. Market analysis, by country

8.3. Pharmacy & drug store

8.3.1. Market size and forecast, by region
8.3.2. Market analysis, by country

8.4. e-Commerce

8.4.1. Market size and forecast, by region
8.4.2. Market analysis, by country

CHAPTER 9: ACNE MEDICATION MARKET, BY REGION

9.1. Overview

9.1.1. Market size and forecast

9.2. North America

9.2.1. Key market trends, growth factors and opportunities
9.2.2. North America acne medication market, by country

9.2.2.1. U.S.

9.2.2.1.1. Market size and forecast, by therapeutic class
9.2.2.1.2. Market size and forecast, by type
9.2.2.1.3. Market size and forecast, by acne type
9.2.2.1.4. Market size and forecast, by distribution channel

9.2.2.2. Canada

9.2.2.2.1. Market size and forecast, by therapeutic class
9.2.2.2.2. Market size and forecast, by type
9.2.2.2.3. Market size and forecast, by acne type
9.2.2.2.4. Market size and forecast, by distribution channel

9.2.2.3. Mexico

9.2.2.3.1. Market size and forecast, by therapeutic class
9.2.2.3.2. Market size and forecast, by type
9.2.2.3.3. Market size and forecast, by acne type
9.2.2.3.4. Market size and forecast, by distribution channel

9.2.3. North America market size and forecast, by therapeutic class
9.2.4. North America market size and forecast, by formulation
9.2.5. North America market size and forecast, by type
9.2.6. North America market size and forecast, by acne type
9.2.7. North America market size and forecast, by distribution channel

9.3. Europe

9.3.1. Key market trends, growth factors and opportunities
9.3.2. Europe market size and forecast, by country

9.3.2.1. Germany

9.3.2.1.1. Market size and forecast, by therapeutic class
9.3.2.1.2. Market size and forecast, by type
9.3.2.1.3. Market size and forecast, by acne type
9.3.2.1.4. Market size and forecast, by distribution channel

9.3.2.2. France

9.3.2.2.1. Market size and forecast, by therapeutic class
9.3.2.2.2. Market size and forecast, by type
9.3.2.2.3. Market size and forecast, by acne type
9.3.2.2.4. Market size and forecast, by distribution channel

9.3.2.3. UK

9.3.2.3.1. Market size and forecast, by therapeutic class
9.3.2.3.2. Market size and forecast, by type
9.3.2.3.3. Market size and forecast, by acne type
9.3.2.3.4. Market size and forecast, by distribution channel

9.3.2.4. Italy

9.3.2.4.1. Market size and forecast, by therapeutic class
9.3.2.4.2. Market size and forecast, by type
9.3.2.4.3. Market size and forecast, by acne type
9.3.2.4.4. Market size and forecast, by distribution channel

9.3.2.5. Spain

9.3.2.5.1. Market size and forecast, by therapeutic class
9.3.2.5.2. Market size and forecast, by type
9.3.2.5.3. Market size and forecast, by acne type
9.3.2.5.4. Market size and forecast, by distribution channel

9.3.3. Rest of Europe

9.3.3.1.1. Market size and forecast, by therapeutic class
9.3.3.1.2. Market size and forecast, by type
9.3.3.1.3. Market size and forecast, by acne type
9.3.3.1.4. Market size and forecast, by distribution channel

9.3.4. Europe market size and forecast, by therapeutic class
9.3.5. Europe market size and forecast, by formulation
9.3.6. Europe market size and forecast, by type
9.3.7. Europe market size and forecast, by acne type
9.3.8. Europe market size and forecast, by distribution channel

9.4. Asia-Pacific

9.4.1. Key market trends, growth factors and opportunities
9.4.2. Asia-Pacific market size and forecast, by country

9.4.2.1. Japan

9.4.2.1.1. Market size and forecast, by therapeutic class
9.4.2.1.2. Market size and forecast, by type
9.4.2.1.3. Market size and forecast, by acne type
9.4.2.1.4. Market size and forecast, by distribution channel

9.4.2.2. China

9.4.2.2.1. Market size and forecast, by therapeutic class
9.4.2.2.2. Market size and forecast, by type
9.4.2.2.3. Market size and forecast, by acne type
9.4.2.2.4. Market size and forecast, by distribution channel

9.4.2.3. India

9.4.2.3.1. Market size and forecast, by therapeutic class
9.4.2.3.2. Market size and forecast, by type
9.4.2.3.3. Market size and forecast, by acne type
9.4.2.3.4. Market size and forecast, by distribution channel

9.4.2.4. Australia

9.4.2.4.1. Market size and forecast, by therapeutic class
9.4.2.4.2. Market size and forecast, by type
9.4.2.4.3. Market size and forecast, by acne type
9.4.2.4.4. Market size and forecast, by distribution channel

9.4.2.5. South Korea

9.4.2.5.1. Market size and forecast, by therapeutic class
9.4.2.5.2. Market size and forecast, by type
9.4.2.5.3. Market size and forecast, by acne type
9.4.2.5.4. Market size and forecast, by distribution channel

9.4.2.6. Rest of Asia-Pacific

9.4.2.6.1. Market size and forecast, by therapeutic class
9.4.2.6.2. Market size and forecast, by type
9.4.2.6.3. Market size and forecast, by acne type
9.4.2.6.4. Market size and forecast, by distribution channel

9.4.3. Asia-Pacific market size and forecast, by therapeutic class
9.4.4. Asia-Pacific market size and forecast, by formulation
9.4.5. Asia-Pacific market size and forecast, by type
9.4.6. Asia-Pacific market size and forecast, by acne type
9.4.7. Asia-Pacific market size and forecast, by distribution channel

9.5. LAMEA

9.5.1. Key market trends, growth factors and opportunities
9.5.2. LAMEA market size and forecast, by country

9.5.2.1. Brazil

9.5.2.1.1. Market size and forecast, by therapeutic class
9.5.2.1.2. Market size and forecast, by type
9.5.2.1.3. Market size and forecast, by acne type
9.5.2.1.4. Market size and forecast, by distribution channel

9.5.2.2. Saudi Arabia

9.5.2.2.1. Market size and forecast, by therapeutic class
9.5.2.2.2. Market size and forecast, by type
9.5.2.2.3. Market size and forecast, by acne type
9.5.2.2.4. Market size and forecast, by distribution channel

9.5.2.3. South Africa

9.5.2.3.1. Market size and forecast, by therapeutic class
9.5.2.3.2. Market size and forecast, by type
9.5.2.3.3. Market size and forecast, by acne type
9.5.2.3.4. Market size and forecast, by distribution channel

9.5.2.4. Rest of LAMEA

9.5.2.4.1. Market size and forecast, by therapeutic class
9.5.2.4.2. Market size and forecast, by type
9.5.2.4.3. Market size and forecast, by acne type
9.5.2.4.4. Market size and forecast, by distribution channel

9.5.3. LAMEA market size and forecast, by therapeutic class
9.5.4. LAMEA market size and forecast, by formulation
9.5.5. LAMEA market size and forecast, by type
9.5.6. LAMEA market size and forecast, by acne type
9.5.7. LAMEA market size and forecast, by distribution channel

CHAPTER 10: COMPANY PROFILES

10.1. Allergan Plc

10.1.1. Company overview
10.1.2. Company snapshot
10.1.3. Operating business segments
10.1.4. Product portfolio
10.1.5. Business performance
10.1.6. Key strategic moves and developments

10.2. Nestle S.A. (Galderma S.A.)

10.2.1. Company overview
10.2.2. Company snapshot
10.2.3. Operating business segments
10.2.4. Product portfolio
10.2.5. Business performance
10.2.6. Key strategic moves and developments

10.3. Johnson & Johnson

10.3.1. Company overview
10.3.2. Company snapshot
10.3.3. Operating business segments
10.3.4. Product portfolio
10.3.5. Business performance

10.4. Mayne Pharma Group Limited

10.4.1. Company overview
10.4.2. Company snapshot
10.4.3. Operating business segments
10.4.4. Product portfolio
10.4.5. Business performance
10.4.6. Key strategic moves and developments

10.5. Mylan N.V.

10.5.1. Company overview
10.5.2. Company snapshot
10.5.3. Operating business segments
10.5.4. Product portfolio
10.5.5. Business performance

10.6. Pfizer Inc.

10.6.1. Company overview
10.6.2. Company snapshot
10.6.3. Operating business segments
10.6.4. Product portfolio
10.6.5. Business performance
10.6.6.

10.7. GlaxoSmithKline Plc (Stiefel Laboratories, Inc.)

10.7.1. Company overview
10.7.2. Company snapshot
10.7.3. Operating business segments
10.7.4. Product portfolio
10.7.5. Business performance

10.8. Sun Pharmaceutical Industries Limited

10.8.1. Company overview
10.8.2. Company snapshot
10.8.3. Operating business segments
10.8.4. Product portfolio
10.8.5. Business performance
10.8.6. Key strategic moves and developments

10.9. Teva Pharmaceutical Industries Ltd.

10.9.1. Company overview
10.9.2. Company snapshot
10.9.3. Operating business segments
10.9.4. Product portfolio
10.9.5. Business performance
10.9.6. Key strategic moves and developments

10.10. Valeant Pharmaceuticals International, Inc.

10.10.1. Company overview
10.10.2. Company snapshot
10.10.3. Operating business segments
10.10.4. Product portfolio
10.10.5. Business performance
10.10.6. Key strategic moves and developments